4 Firms Build Amneal's Up To $1.1B Kashiv Biosimilars Buy
law360
1 month ago
34 views
Biopharmaceutical company Amneal Pharmaceuticals Inc. on Wednesday unveiled plans to acquire biosimilars-focused Kashiv BioSciences LLC in a deal worth up to $1.1 billion that was built by four law firms.
Continue Reading
Sign up for FREE to read the full article and access 124K+ alternative investment headlines.